annb0t
Top 20
Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema
KING OF PRUSSIA, Pa., March 1, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE). The Lancet paper provi...
>>> Read more: The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
KING OF PRUSSIA, Pa., March 1, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE). The Lancet paper provi...
>>> Read more: The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
